Latest California Healthline Stories
Journalists Dig Into Questions About the 988 Hotline and Inflation Reduction Act
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.
KHN’s ‘What the Health?’: Wrapping Up Summer’s Health News
President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN’s Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
Inflation Reduction Act Contains Important Cost-Saving Changes for Many Patients — Maybe for You
The legislation, which the House is expected to pass Friday, would allow the federal government, for the first time, to negotiate the price of some drugs that Medicare buys. It also would extend the enhanced subsidies for people who buy insurance on the Affordable Care Act marketplaces.
KHN’s ‘What the Health?’: A Big Week for Biden
Congress is leaving for its annual summer break having accomplished far more than many expected, including, barring unforeseen snags, a bill to address the cost of prescription drugs for Medicare beneficiaries and extend the enhanced subsidies for insurance premiums under the Affordable Care Act. Meanwhile, the abortion issue continues to roil the nation as Indiana becomes the first state to ban the procedure in almost all cases since the Supreme Court overruled the constitutional right to abortion in June. Alice Miranda Ollstein of Politico, Sarah Karlin-Smith of the Pink Sheet, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more.
No, the Senate-Passed Reconciliation Bill Won’t Strip $300 Billion From Medicare
Under the Medicare drug negotiations provisions in the reconciliation bill, the federal government would see its outlays reduced by about $300 billion. That reduction wouldn’t result from cuts in benefits. Instead, Medicare would be empowered to leverage its market power to pay lower prices for certain drugs.
Watch: The Nitty-Gritty of Medicare Drug Price Negotiations — And Patients’ Potential Savings
KHN chief Washington correspondent Julie Rovner discusses the Senate Democrats’ plans to let Medicare negotiate some drug prices, cap out-of-pocket drug costs for seniors, and fund enhanced subsides for ACA marketplace health plans.
Hospices Have Become Big Business for Private Equity Firms
Private equity firms are seeing opportunities for profit in hospice care, once the domain of nonprofit organizations. The investment companies are transforming the industry — and might be jeopardizing patient care — in the process.
Ad Targeting Manchin and AARP Mischaracterizes Medicare Drug-Price Negotiations
The advocacy group American Commitment said empowering Medicare to negotiate drug prices would raid it of billions of dollars. Drug pricing experts say that that’s not the case and that such policies would instead reduce costs for the Medicare program and seniors.
KHN’s ‘What the Health?’: Drug Price Bill Is a Go in the Senate
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN’s Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
KHN’s ‘What the Health?’: Life After ‘Roe’ Is … Confusing
A rapidly changing landscape for abortion has left patients, providers, employers, and lawmakers alike wondering what is and is not legal and what to do next. Meanwhile, Democrats in Congress have resumed negotiations on legislation to lower drug prices and, potentially, continue expanded insurance subsidies for the Affordable Care Act. Alice Miranda Ollstein of Politico, Tami Luhby of CNN, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.